-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target

Benzinga·03/31/2026 14:01:19
Listen to the news
Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and maintains $8 price target.